Handbook of Parkinson's DiseaseRajesh Pahwa, Kelly E. Lyons CRC Press, 25 mar. 2003 - 624 pagini The third edition of this reference has new and fully updated chapters that feature discoveries and breakthroughs in the diagnosis and management of Parkinson's disease. |
Cuprins
Chapter 1 Early Iconography of Parkinsons Disease | 1 |
Chapter 2 Epidemiology of Parkinsonism | 17 |
Chapter 3 Differential Diagnosis of Parkinsonism | 43 |
Chapter 4 Pathophysiology and Clinical Assessment of Parkinsonian Symptoms and Signs | 71 |
Chapter 5 Nonmotor Symptoms of Parkinsons Disease | 109 |
Chapter 6 Neuropsychological Aspects of Parkinsons Disease and Parkinsonian Syndromes | 127 |
Chapter 7 Management of Neurobehavioral Symptoms in Parkinsons Disease | 159 |
Chapter 8 Neuroimaging in Parkinsons Disease | 179 |
Chapter 16 Amantadine and Anticholinergics | 363 |
Chapter 17 Levodopa | 381 |
Chapter 18 Dopamine Agonists | 407 |
Chapter 19 Monoamine Oxidase Inhibitors in Parkinsons Disease | 425 |
Chapter 20 CatecholOMethyltransferase in Parkinsons Disease | 437 |
Chapter 21 Investigational Pharmacological Treatments for Parkinsons Disease | 453 |
Chapter 22 Lesion Surgeries | 463 |
Chapter 23 Deep Brain Stimulation in Parkinsons Disease | 497 |
Chapter 9 Neuropathology of Parkinsonism | 203 |
Chapter 10 Neurochemistry of Nigral Degeneration | 221 |
Chapter 11 NeurophysiologyCircuitry | 249 |
Chapter 12 Animal Models of Parkinsons Disease and Related Disorders | 277 |
Anatomy Function and Relevance to Parkinsons Disease | 305 |
Chapter 14 Genetics | 325 |
Chapter 15 Environmental Risk Factors for Parkinsons Disease | 339 |
Chapter 24 Neural Transplantation in Parkinsons Disease | 517 |
An Interdisciplinary Approach | 541 |
555 | |
About the Editors | 599 |
Back Cover | 600 |
Termeni și expresii frecvente
activity agonists animal Ann Neurol assessment associated basal behavioral benefit bilateral brain cause cells changes clinical cognitive common compared complications degeneration dementia demonstrated depression diagnosis dopamine dopaminergic dose drug dysfunction dyskinesias early effects et al evaluation evidence exposure expression factors findings fluctuations function gene grafts human imaging impairment important improvement increased inhibition inhibitors initial lesions levels levodopa Lewy bodies loss mechanisms medications months motor Mov Disord movement MPTP Neurology neurons Neurosci Neurosurg normal nucleus observed occur onset pallidotomy Parkinson’s disease parkinsonian pathological pathway patients PD patients potential present progression protein Psychiatry receptors reduced relatively reported response rigidity risk role scores seen severe showed side significant similar specific stimulation striatal striatum subjects substantia nigra suggest symptoms syndrome therapy transplantation treated treatment tremor trials UPDRS